Novo Nordisk Statistics
Total Valuation
Novo Nordisk has a market cap or net worth of $575.53 billion. The enterprise value is $578.09 billion.
| Market Cap | 575.53B |
| Enterprise Value | 578.09B |
Important Dates
The next confirmed earnings date is Wednesday, August 7, 2024, before market open.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | Mar 22, 2024 |
Share Statistics
Novo Nordisk has 4.54 billion shares outstanding.
| Shares Outstanding | 4.54B |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 9.76% |
| Float | 3.19B |
Valuation Ratios
The trailing PE ratio is 43.83 and the forward PE ratio is 39.53. Novo Nordisk's PEG ratio is 2.36.
| PE Ratio | 43.83 |
| Forward PE | 39.53 |
| PS Ratio | 16.28 |
| Forward PS | 1.86 |
| PB Ratio | 40.00 |
| P/FCF Ratio | 61.99 |
| PEG Ratio | 2.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.35, with an EV/FCF ratio of 62.27.
| EV / Earnings | 44.74 |
| EV / Sales | 16.36 |
| EV / EBITDA | 32.35 |
| EV / EBIT | 35.41 |
| EV / FCF | 62.27 |
Financial Position
The company has a current ratio of 0.70, with a Debt / Equity ratio of 0.27.
| Current Ratio | 0.70 |
| Quick Ratio | 0.40 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | 0.22 |
| Debt / FCF | 0.42 |
| Interest Coverage | 296.91 |
Financial Efficiency
Return on equity (ROE) is 91.80% and return on invested capital (ROIC) is 69.40%.
| Return on Equity (ROE) | 91.80% |
| Return on Assets (ROA) | 29.90% |
| Return on Capital (ROIC) | 69.40% |
| Revenue Per Employee | $549,547 |
| Profits Per Employee | $200,871 |
| Employee Count | 64,319 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Novo Nordisk has paid $3.28 billion in taxes.
| Income Tax | 3.28B |
| Effective Tax Rate | 20.27% |
Stock Price Statistics
The stock price has increased by +60.13% in the last 52 weeks. The beta is 0.15, so Novo Nordisk's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +60.13% |
| 50-Day Moving Average | 138.35 |
| 200-Day Moving Average | 119.53 |
| Relative Strength Index (RSI) | 32.28 |
| Average Volume (20 Days) | 4,190,915 |
Short Selling Information
| Short Interest | 3.15M |
| Short Previous Month | 4.36M |
| Short % of Shares Out | 0.10% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.83 |
Income Statement
In the last 12 months, Novo Nordisk had revenue of $35.35 billion and earned $12.92 billion in profits. Earnings per share was $2.90.
| Revenue | 35.35B |
| Gross Profit | 30.08B |
| Operating Income | 15.92B |
| Pretax Income | 16.27B |
| Net Income | 12.92B |
| EBITDA | 17.87B |
| EBIT | 16.33B |
| Earnings Per Share (EPS) | $2.90 |
Balance Sheet
The company has $1.35 billion in cash and $3.92 billion in debt, giving a net cash position of -$2.56 billion or -$0.56 per share.
| Cash & Cash Equivalents | 1.35B |
| Total Debt | 3.92B |
| Net Cash | -2.56B |
| Net Cash Per Share | -$0.56 |
| Equity (Book Value) | 14.39B |
| Book Value Per Share | 3.17 |
| Working Capital | -7.15B |
Cash Flow
In the last 12 months, operating cash flow was $13.59 billion and capital expenditures -$4.30 billion, giving a free cash flow of $9.28 billion.
| Operating Cash Flow | 13.59B |
| Capital Expenditures | -4.30B |
| Free Cash Flow | 9.28B |
| FCF Per Share | $2.06 |
Margins
Gross margin is 85.09%, with operating and profit margins of 45.03% and 36.55%.
| Gross Margin | 85.09% |
| Operating Margin | 45.03% |
| Pretax Margin | 46.03% |
| Profit Margin | 36.55% |
| EBITDA Margin | 50.56% |
| EBIT Margin | 46.19% |
| FCF Margin | 26.27% |
Dividends & Yields
This stock pays an annual dividend of $0.98, which amounts to a dividend yield of 0.77%.
| Dividend Per Share | $0.98 |
| Dividend Yield | 0.77% |
| Dividend Growth (YoY) | 55.68% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 33.72% |
| Buyback Yield | 1.10% |
| Shareholder Yield | 1.87% |
| Earnings Yield | 2.24% |
| FCF Yield | 1.61% |
Analyst Forecast
The average price target for Novo Nordisk is $140.50, which is 10.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $140.50 |
| Price Target Difference | 10.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 15.83% |
| EPS Growth Forecast (5Y) | 16.68% |
Stock Splits
The last stock split was on September 20, 2023. It was a forward split with a ratio of 2:1.
| Last Split Date | Sep 20, 2023 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Novo Nordisk has an Altman Z-Score of 14.19 and a Piotroski F-Score of 8.
| Altman Z-Score | 14.19 |
| Piotroski F-Score | 8 |